These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18841276)

  • 1. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
    Hedner U
    Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
    Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
    Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor VIIa: its background, development and clinical use.
    Hedner U
    Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
    Petrini P; Klementz G
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
    Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant activated factor VII as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of factor VIIa in the treatment of coagulopathies.
    Hedner U
    Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():77-85. PubMed ID: 16673269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action, development and clinical experience of recombinant FVIIa.
    Hedner U
    J Biotechnol; 2006 Aug; 124(4):747-57. PubMed ID: 16697480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
    Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
    Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
    Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
    Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
    Łaguna P; Mital A
    Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
    Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
    Kavakli K; Makris M; Zulfikar B; Erhardtsen E; Abrams ZS; Kenet G;
    Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.